


PHARMACEUTICAL 2022

Ovid Therapeutics Inc. Rank 2 of 475







PHARMACEUTICAL 2022



Ovid Therapeutics Inc. Rank 2 of 475



The relative strengths and weaknesses of Ovid Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ovid Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,005% points. The greatest weakness of Ovid Therapeutics Inc. is the variable Other Compr. Net Income, reducing the Economic Capital Ratio by 0.016% points.

The company's Economic Capital Ratio, given in the ranking table, is 665%, being 942% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	190,479
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,798
Liabilities, Non-Current	0
Other Assets	3,823
Other Compr. Net Income	0
Other Expenses	1,329
Other Liabilities	0
Other Net Income	-46
Property and Equipment	243
Research and Development	46,940
Revenues	208,383
Selling, General and Administrative Expense	37,234

Output Variable	Value in 1000 USD
Assets	194,545
Liabilities	14,798
Expenses	85,503
Stockholders Equity	179,746
Net Income	122,835
Comprehensive Net Income	122,835
Economic Capital Ratio	665%